Evidence map›Paper›PMID 35370735›Full record

ArticleFrontiers in pharmacology2022

Gha-Hyun J Kim, Han Mo, Harrison Liu, Meri Okorie, Steven Chen, Jiashun Zheng, Hao Li, Michelle Arkin, Bo Huang, Su Guo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Gha-Hyun J KimDepartment of Bioengineering and Therapeutic Sciences and Programs in Biological Sciences and Human Genetics, University of California San Francisco, San Francisco, CA, United States.
Han MoDepartment of Bioengineering and Therapeutic Sciences and Programs in Biological Sciences and Human Genetics, University of California San Francisco, San Francisco, CA, United States.
Harrison LiuDepartment of Pharmaceutical Chemistry, San Francisco, CA, United States.
Meri OkorieDepartment of Bioengineering and Therapeutic Sciences and Programs in Biological Sciences and Human Genetics, University of California San Francisco, San Francisco, CA, United States.
Steven ChenDepartment of Pharmaceutical Chemistry, San Francisco, CA, United States.
Jiashun ZhengDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, United States.
Hao LiDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, United States.
Michelle ArkinDepartment of Pharmaceutical Chemistry, San Francisco, CA, United States.
Bo HuangDepartment of Pharmaceutical Chemistry, San Francisco, CA, United States.
Su GuoDepartment of Bioengineering and Therapeutic Sciences and Programs in Biological Sciences and Human Genetics, University of California San Francisco, San Francisco, CA, United States.
University of California, San Francisco · USChan Zuckerberg Initiative (United States) · USTsinghua University · CN

Funding

PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1M
Pharmaceutical Sciences and PharmacogenomicsT32GM142516 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Su Guo · 2022 to 2026
$2.4M
Mechanisms of renin-angiotensin signaling in programmed and insult-induced neuronal deathR01NS120219 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GUO, SU · 2021 to 2025
$2.0M
Reconstructing the Global Epistasis Network for AgingR21AG071899 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, HAO · 2021 to 2022
$444k
Advancing Whole-Organism Screening for Chemical Modifiers of the BrainR21NS082938 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ABATE, ADAM R., GUO, SU · 2013 to 2014
$410k
NIA NIH HHS R21 AG071899NIGMS NIH HHS T32 GM007175NIGMS NIH HHS T32 GM142516NINDS NIH HHS R01 NS120219NINDS NIH HHS R21 NS082938
6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder with prominent dopamine (DA) neuron degeneration. PD affects millions of people worldwide, but currently available therapies are limited to temporary relief of symptoms. As an effort to discover disease-modifying therapeutics, we have conducted a screen of 1,403 bioactive small molecule compounds using an

Indexed as

aloperinegaucher diseaseGBAlarval screeningneurodegenerationNTR-MTZParkinson’s diseasezebrafish

Identifiers

PMID35370735
PMCPMC8971663
OpenAlexW4220886333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.